Sonoma Pharmaceuticals
SNOA
20 hedge funds and large institutions have $1.19M invested in Sonoma Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 20 → 20 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
0.12% less ownership
Funds ownership: 0.51% → 0.39% (-0.12%)
24% less capital invested
Capital invested by funds: $1.56M → $1.19M (-$370K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$131K |
| 2 |
Squarepoint
New York
|
+$96.8K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$69.4K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$41.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BA
Bard Associates
Chicago,
Illinois
|
-$341K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$38K |
| 3 |
HSA
Hussman Strategic Advisors
Ellicott City,
Maryland
|
-$23K |
| 4 |
Renaissance Technologies
New York
|
-$9.23K |
| 5 |
Morgan Stanley
New York
|
-$493 |
SNOA Hedge Fund Activity: Q3 2021 in Review
20 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q3 2021, worth a combined $1.19M — down 24% from $1.56M a quarter earlier.
Fund positioning in SNOA was balanced in Q3 2021: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 3 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $131K. The largest seller was Bard Associates, exiting entirely with an estimated $341K sold.
- 20 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $1.19M of Sonoma Pharmaceuticals stock for Q3 2021, down 24% quarter-over-quarter.
- 3 funds opened new Sonoma Pharmaceuticals positions in Q3 2021 and 3 closed out, a net change of 0 holders.
- The largest Sonoma Pharmaceuticals buyer in Q3 2021 was Virtu Financial, an estimated $131K added.
- The largest Sonoma Pharmaceuticals seller in Q3 2021 was Bard Associates, an estimated $341K sold.
Based on aggregated 13F filings for Q3 2021.